Cifurtilimab (SEA-CD40) is an agonistic nonfucosylated, humanized IgG1 monoclonal antibody directed against CD40. Cifurtilimab shows antitumor activities.

Cifurtilimab 增强了 FcγRIIIa 结合 (比亲本 IgG1 抗体大 10 倍)，驱动效应因子功能的增强，导致比具有沉默或选择性 FcγR 结合的抗体更强的免疫刺激活性。
暴露于 Cifurtilimab 会导致明显的反应特征，包括 APCs、CD8+ 和 CD4+ T 细胞和 NK 细胞的激活，以及 CD40+ B 细胞的靶向衰竭。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

在临床前小鼠模型中，Cifurtilimab 与化疗药物联合使用可增强抗肿瘤活性。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

在临床前小鼠模型中，Cifurtilimab 与化疗药物联合使用可增强抗肿瘤活性。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

• . Neff-LaFord H, et al. SEA-CD40 is a non-fucosylated anti-CD40 antibody with potent pharmacodynamic activity in preclinical models and patients with advanced solid tumors. Cancer Research, 2020, 80(16_Supplement): 5535-5535.

  . Zeng W, et al. 438 Synergy between SEA-CD40 and chemotherapeutics drives curative antitumor activity in preclinical models. 2020.